

# Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry

Katrin E Schimke,<sup>1</sup> Frida Renström,<sup>1</sup> Sandro Meier,<sup>1</sup> Christoph Stettler,<sup>2</sup> Michael Brändle,<sup>1</sup> the SwissDiab Study Group

**To cite:** Schimke KE, Renström F, Meier S, *et al.* Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry. *BMJ Open Diab Res Care* 2018;**6**:e000454. doi:10.1136/bmjdr-2017-000454

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2017-000454>).

Received 19 July 2017  
Revised 14 December 2017  
Accepted 18 January 2018



<sup>1</sup>Division of Endocrinology and Diabetes, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

<sup>2</sup>Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland

## Correspondence to

Prof. Michael Brändle, Division of Endocrinology and Diabetes, Cantonal Hospital St. Gallen, St. Gallen 9007, Switzerland; [Michael.Braendle@kssg.ch](mailto:Michael.Braendle@kssg.ch)

## ABSTRACT

**Objective** Tight glycaemic control and aggressive treatment of additional cardiovascular risk factors can substantially reduce risk of diabetes-related complications. In 2013, the Swiss Society of Endocrinology and Diabetology (SSED) established national criteria on good disease management in diabetes, but little is known about compliance in clinical care. Here we assessed to what extent patients from two tertiary care centers in the German-speaking part of Switzerland enrolled in the Swiss Diabetes (SwissDiab) Registry adhere to the SSED criteria.

**Research design and methods** SwissDiab is a prospective observational cohort study of patients regularly treated at Swiss tertiary diabetes centers. Data were collected through standardized annual health examinations. Baseline participant descriptive statistics, stratified by diabetes mellitus type 1 (DM1) and type 2 (DM2), were compared with SSED targets for glycaemic control, blood pressure, blood lipids, weight maintenance, and ophthalmic examination.

**Results** By the end of 2016, 604 participants with DM1 (40%) and DM2 (60%) had data available for analyses, 36% and 29% women, respectively. At baseline, all the SSED targets were met with two exceptions: a glycated hemoglobin A1c value <7% was measured in 32% of participants with DM1 (SSED target: ≥40%) and 47% and 56% of overweight or obese participants with DM1 and DM2, respectively, received nutritional counseling in the previous year (SSED target: ≥80%).

**Conclusions** The SSED targets for good disease management in diabetes were achieved in the majority of participants at the time of enrollment, but results also highlight areas where disease management can be improved, particularly the role of nutrition counseling.

## INTRODUCTION

Tight glycaemic control and aggressive treatment of additional cardiovascular risk factors have shown to reduce both microvascular and macrovascular complications of diabetes.<sup>1–4</sup> This has led to treatment standards targeting both therapeutic and process of care parameters. Benefits from adherence to such guidelines have been shown in several studies, including better glycaemic control, lower risk of long-term morbidity and mortality, improved quality of life, and lower healthcare

## Significance of the study

### What is already known about this subject?

► Standardization of diabetes management is known to improve quality of care.

### What are the new findings?

► This study is the first to assess adherence to the Swiss national targets introduced in 2013 for good disease management in diabetes. Overall, the results reflect a high standard of diabetes care in two tertiary centers in the German-speaking part of Switzerland, but also indicate areas where disease management can be improved, particularly the implementation of nutrition counseling.

### How might these results change the focus of research or clinical practice?

► We hope this study will motivate diabetes care centers to evaluate their clinical practices, raising awareness of the current standard of diabetes management and encouraging improvements.

costs.<sup>5–8</sup> However, studies have also shown great disparities between guideline objectives and actual standard of care.<sup>6,9,10</sup>

Data on the current standard of diabetes care in Switzerland are scarce. To fill this gap, two tertiary diabetes care centers in the German-speaking part of Switzerland (St. Gallen and Bern) initiated the Swiss Diabetes (SwissDiab) Registry in 2008, a national multicenter project with the aim to prospectively collect data regarding diabetes management and prevalence and incidence of diabetes-related complications. The first patients were enrolled in 2010. Participants undergo an extensive annual health examination according to a standardized protocol. In 2013, the Swiss Society of Endocrinology and Diabetology (SSED) established national target criteria for good disease management in diabetes. The target criteria are based on the Diabetes Recognition Program established by the American Diabetes Association

(ADA) and the National Committee for Quality Assurance and adapted to the treatment guidelines for Switzerland established by SSED in 2009.<sup>11 12</sup> The criteria target clinical and biochemical parameters relevant to clinical outcomes of diabetes management as well as guiding frequencies of annual screenings and monitoring of diabetes-related complications.<sup>13</sup> However, little is known about compliance in clinical care settings.

The aim of this study was to evaluate compliance with the SSED target criteria for good disease management of diabetes in 604 SwissDiab participants with eligible baseline data at the time of analysis.

## RESEARCH DESIGN AND METHODS

### Study participants

SwissDiab is an ongoing prospective observational cohort study enrolling patients with diabetes regularly seen and treated at Swiss tertiary diabetes care centers. Eligible are patients  $\geq 18$  years of age, regardless of diabetes type (gestational diabetes excluded), duration, or treatment. Patients with a life expectancy  $< 1$  year due to severe comorbidity (eg, end-stage cancer) or unable to comply with the study protocol (eg, due to mental disorder or drug abuse) are excluded at the discretion of the attending physician. Diabetes is defined according to ADA (glycated hemoglobin A1c (HbA1c)  $\geq 6.5\%$  ( $\geq 48$  mmol/mol) or fasting plasma glucose  $\geq 7$  mmol/L or random plasma glucose  $\geq 11.1$  mmol/L plus typical symptoms or 2-hour plasma glucose  $\geq 11.1$  mmol/L following a 75 g oral glucose tolerance test).<sup>14</sup> Patients under treatment with  $\geq 2$  oral hypoglycemic agents and/or insulin in the absence of a clinical diagnosis (as defined above) are also included. Diabetes type is diagnosed clinically in most cases, supported by autoantibody status where appropriate.<sup>15</sup>

The present study includes data from the two initial centers in the German-speaking part of Switzerland, the Division of Diabetes, Endocrinology, Nutritional Medicine, and Metabolism, Inselspital Bern, University Hospital, Bern, and the Division of Endocrinology and Diabetes at the Cantonal Hospital of St. Gallen. All participants provided written informed consent.

### Research design and methods

Patient-related data were collected through a standardized annual health examination, comprising the following domains.

#### Diabetes-specific medical history

Information relevant to the care and management of diabetes (eg, diabetes type, date of diagnosis, family history, treatment history (including drug class and dosages), hypoglycemic events, and diabetes-related complications) was obtained from the patient history, supplemented by information retrieved from other sources like patient records where appropriate.

### Clinical and anthropometric measurements

Clinical examinations were conducted by trained medical staff experienced in epidemiological and clinical studies. Weight (to the nearest 0.1 kg) was measured with participants wearing light clothes and no shoes. Height (to the nearest 0.5 cm) was measured using a wall-mounted stadiometer. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Waist circumference was measured at the widest point using a non-stretchable tape. At baseline, systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured once on each arm following a 5 min rest with the participant in a seated position. The mean of the two measurements was used.

### Biochemistry

Participants arrived at the study center following an overnight fast ( $\geq 7.5$  hours), having been instructed to take their antihypertensive medication as prescribed. Fasted blood was drawn from the antecubital vein and further processed. HbA1c was determined using a Diabetes Control and Complications Trial (DCCT)/UK Prospective Diabetes Study (UKPDS) traceable assay. Serum total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol, and triglycerides were measured according to routine methods at the laboratory medicine at each center. Aliquots of serum and whole blood were stored at  $-80^{\circ}\text{C}$ .

### Criteria for good disease management in diabetes

The SSED criteria for good disease management in diabetes define treatment targets in eight domains to guide diabetes-specific standard of care in Switzerland.<sup>13</sup> The current analysis focused on a subset of criteria related to clinical and biochemical targets, and frequencies of nutrition counseling and ophthalmic examination. The remaining treatment objectives were excluded from the analysis as they were either part of the SwissDiab annual health examination (ie, foot exam, and screening for neuropathy and nephropathy) and thus performed in all participants or information was not collected (eg, physical activity counseling if BMI  $\geq 25$  kg/m<sup>2</sup>, and smoking cessation counseling in active smokers). Specifically, compliance with the treatment targets in the following five domains was assessed:

1. HbA1c:
  - $\geq 9.0\%$  (75 mmol/mol) in  $< 15\%$  of patients
  - $< 8.0\%$  (64 mmol/mol) in  $\geq 60\%$  of patients
  - $< 7.0\%$  (53 mmol/mol) in  $\geq 40\%$  of patients
2. BP  $\geq 140/90$  mm Hg in  $< 35\%$  of patients
3. LDL-cholesterol levels in patients  $< 75$  years of age:
  - $\geq 3.37$  mmol/L in  $< 37\%$  of patients
  - $< 2.6$  mmol/L in  $\geq 36\%$  of patients
4. Annual nutrition counseling in  $\geq 80\%$  of patients with a BMI  $\geq 25$  kg/m<sup>2</sup>
5. Annual standard ophthalmic examination in  $\geq 60\%$  of patients

The current analysis was based on data collected during the baseline annual health examination. Data

from both study centers were pooled and analyses were stratified by diabetes mellitus type 1 (DM1) and type 2 (DM2). In secondary analyses, further stratification was done by time since diagnosis ( $\leq 5$  years or  $> 5$  years) to explore whether diabetes duration influences treatment outcomes. Descriptive statistics were computed as medians and IQR for continuous variables and percentages for dichotomous variables. Between-group differences were determined using two-sided Wilcoxon rank-sum test for continuous variables and  $\chi^2$  test for categorical variables. All analyses were performed using SAS V.9.3 (SAS Institute).

## RESULTS

### Baseline participant characteristics

By 31 December 2016 data for 674 SwissDiab participants were available for analysis, 55% (n=371) of them recruited in St. Gallen and 45% (n=303) in Bern, constituting 248 cases (37%) of DM1, 375 cases (55%) of DM2, and 51 cases (8%) of rarer forms of diabetes (eg, monogenic and drug-induced diabetes). The latter group was excluded from the analysis. Participants lacking HbA1c (2%) or with implausible data (BMI  $< 15$  or  $> 90$  kg/m<sup>2</sup> (1%)) were excluded, leaving 239 participants with

DM1 and 365 participants with DM2 eligible for analysis. Baseline descriptive characteristics of the 604 SwissDiab participants included in the analysis are shown in table 1.

### Compliance with SSED criteria for good disease management of diabetes

Table 2 shows the proportion of SwissDiab participants fulfilling the criteria for good glycemic and BP control established by the SSED.<sup>13</sup> The proportion of participants with an HbA1c  $\geq 9\%$ , and an HbA1c  $< 8\%$  comply with the SSED targets ( $< 15\%$  and  $\geq 60\%$ , respectively), regardless of diabetes type and with no statistically significant difference between the DM1 and DM2 group. The SSED target of an HbA1c  $< 7\%$  in  $\geq 40\%$  of patients was only achieved in the group with DM2. The proportion of participants with high BP ( $\geq 140/90$  mm Hg) was within the SSED target ( $< 35\%$ ) in both the DM1 and DM2 groups.

As shown in table 3, although the SSED targets for LDL-cholesterol levels in patients  $< 75$  years of age were achieved in both the DM1 and DM2 groups, the proportion tended to be greater in the DM2 group.

Regardless of diabetes type, the majority of participants underwent at least one ophthalmic examination during the year prior to the baseline SwissDiab examination.

**Table 1** Baseline characteristics of Swiss Diabetes Registry participants, stratified by diabetes type (n=604)

Characteristics	n	DM1	n	DM2	P-diff*
Participants, %	239	39.6	365	60.4	–
Females, %	87	36.4	105	28.8	0.05
Age, years	239	39.9 (28.3–53.4)	365	62.1 (54.7–68.8)	$< 0.0001$
Age at diagnosis, years	238	18.0 (12.0–35.0)	362	48.0 (42.0–56.0)	$< 0.0001$
Years since diagnosis, years	238	15.0 (7.0–24.0)	362	12.0 (6.0–18.0)	0.0003
Higher education, %†	105‡	44.1	99§	27.3	$< 0.0001$
Migration background, %	43‡	18.1	123§	33.9	$< 0.0001$
BMI, kg/m <sup>2</sup>	239	24.6 (22.2–27.0)	365	32.1 (28.4–36.5)	$< 0.0001$
BMI $\geq 25$ kg/m <sup>2</sup> , %	109	45.6	341	93.4	$< 0.0001$
Waist circumference, cm	233	91.0 (83.0–98.0)	346	110.0 (101.0–122.0)	$< 0.0001$
Systolic BP, mm Hg	236	128.0 (120.0–137.5)	363	138.0 (127.0–149.5)	$< 0.0001$
Diastolic BP, mm Hg	236	76.0 (71.5–82.8)	363	77.5 (72.0–83.5)	0.32
Current smokers, %	49‡	20.6	71§	19.6	0.76
HbA1c, %	239	7.4 (6.8–8.0)	365	7.1 (6.6–7.9)	0.01
HbA1c, mmol/mol	239	57.4 (50.8–63.9)	365	54.1 (48.6–62.8)	0.01
Triglycerides, mmol/L	237	0.9 (0.6–1.3)	363	1.9 (1.2–2.8)	$< 0.0001$
Total cholesterol, mmol/L	238	4.5 (4.0–5.3)	363	4.1 (3.6–4.9)	$< 0.0001$
HDL-cholesterol, mmol/L	238	1.6 (1.3–2.0)	363	1.1 (1.0–1.3)	$< 0.0001$
LDL-cholesterol, mmol/L	238	2.6 (2.2–3.1)	363	2.4 (1.9–2.9)	$< 0.0001$

Data are median (IQR), or frequency (%).

\*Two-sided Wilcoxon rank-sum test for continuous and  $\chi^2$  test for categorical variables.

†College or university degree.

‡Information missing in one participant.

§Information missing in two participants.

BMI, body mass index; BP, blood pressure; DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.



**Table 2** Proportion of Swiss Diabetes Registry participants fulfilling the Swiss Society of Endocrinology and Diabetology (SSED) criteria for glycaemic and blood pressure (BP) control at baseline, stratified by diabetes type (n=604)

SSED Criterion	SSED target (%)	DM1 (n=239)	DM2 (n=365)	P-diff
HbA1c $\geq$ 9% (75 mmol/mol)	<15	n=20, <b>8%</b>	n=28, <b>8%</b>	0.76
HbA1c<8% (64 mmol/mol)	$\geq$ 60	n=179, <b>75%</b>	n=281, <b>77%</b>	0.56
HbA1c<7% (53 mmol/mol)	$\geq$ 40	n=76, <b>32%</b>	n=159, <b>44%</b>	0.004
BP $\geq$ 140/90 mm Hg	<35	n=7*, <b>3%</b>	n=28†, <b>8%</b>	0.02

Group estimates that meet the SSED targets are highlighted in bold. Between-group differences determined with the  $\chi^2$  test.

\*Information missing in three participants.

†Information missing in two participants.

DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; HbA1c, glycated hemoglobin A1c.

The SSED target of  $\geq$ 80% was achieved in both the DM1 (88.4%, n=206, data missing in six participants) and DM2 groups (90.4%, n=328, data missing in two participants), with no statistically significant difference between the groups (P-difference=0.45).

Of the 109 participants with DM1 and a BMI $\geq$ 25 kg/m<sup>2</sup>, information on nutrition counseling was available in 104 participants. Of these, 47.1% (n=49) received nutrition counseling in the previous year. In the DM2 group, 93.4% (n=341) were overweight or obese, and 56.1% (n=184) received nutrition counseling in the previous year (information missing in 13 overweight or obese participants). Neither group thus achieved the SSED target of  $\geq$ 80%.

#### Stratification based on time since diagnosis

The 39 participants diagnosed with DM1  $\leq$ 5 years ago (information missing for one participant) were older at the time of diagnosis compared with the 199 participants diagnosed >5 years ago (36.0 years (27.0–49.0) vs 16.0 years (11.0–31.0), P-difference <0.0001) with a lower average HbA1c (7.0% (6.3–7.8) vs 7.4% (6.9–8.0), P-difference=0.04). Compared with the 282 participants diagnosed with DM2 >5 years ago (information missing for three participants), the 80 participants diagnosed with DM2  $\leq$ 5 years ago were younger (56.5 years (49.9–63.2) vs 63.9 years (56.6–70.1), P-difference <0.0001) and received their diagnosis at an older age (55.0 years (46.5–60.5) vs 47.0 years (41.0–54.0), P-difference <0.0001). The latter group had a lower average HbA1c (6.6% (6.1–7.3) vs 7.3% (6.7–8.0), P-difference <0.0001) and higher total cholesterol (4.5 mmol/L (4.0–5.4) vs 4.0 mmol/L

(3.5–4.7), P-difference <0.0001) and LDL-cholesterol (2.7 mmol/L (2.1–3.3) vs 2.3 mmol/L (1.8–2.7), P-difference <0.0001) levels. The complete set of participant characteristics stratified by diabetes type and time since diagnosis are available in online supplementary table 1.

The SSED target of an HbA1c<7% in  $\geq$ 40% of patients was achieved among participants diagnosed with DM1  $\leq$ 5 years ago but not among participants diagnosed >5 years ago (P-difference=0.01). Of the 39 participants diagnosed with DM1  $\leq$ 5 years ago, 48.7% (n=19) fulfilled the SSED criterion of an HbA1c<7%, achieving the SSED target of  $\geq$ 40%. Among the 199 participants diagnosed with DM1 >5 years ago, 28.6% (n=57) fulfilled the SSED criterion.

Among participants with DM2, the SSED target of an HbA1c<7% in  $\geq$ 40% of patients was achieved in the group of participants diagnosed with DM2  $\leq$ 5 years ago but not in the participants diagnosed >5 years ago (P-difference <0.0001). Of the 80 participants diagnosed with DM2  $\leq$ 5 years ago, 63.8% (n=51) fulfilled the SSED criterion, achieving the target of  $\geq$ 40%. Among the 282 participants diagnosed with DM2 >5 years ago, 38.3% (n=108) fulfilled the SSED criterion.

Among participants with DM2, the SSED target of an LDL-cholesterol level of  $\geq$ 3.37 mmol/L in <37% of patients was achieved in both the group diagnosed  $\leq$ 5 years ago (n=78, data missing in two participants) and >5 years ago (n=256, data missing in two participants), but to a greater extent in the latter (24.4% (n=19) vs 9.4% (n=24), respectively, P-difference=0.0005). A similar

**Table 3** Proportion of Swiss Diabetes Registry participants <75 years of age fulfilling the Swiss Society of Endocrinology and Diabetology (SSED) criteria for low-density lipoprotein (LDL)-cholesterol at baseline, stratified by diabetes type

LDL-cholesterol	SSED target (%)	DM1 (n=235)*	DM2 (n=336)†	P-diff
$\geq$ 3.37 mmol/L	<37	n=43, <b>18%</b>	n=43, <b>13%</b>	0.07
<2.6 mmol/L	$\geq$ 36	n=112, <b>48%</b>	n=198, <b>59%</b>	0.008

Group estimates that meet the SSED target criteria are highlighted in bold. Between-group differences determined with the  $\chi^2$  test.

\*One participant excluded due to missing LDL-cholesterol data.

†Two participants excluded due to missing LDL-cholesterol data.

DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2.

result was obtained for the SSED target of an LDL-cholesterol level of  $<2.6$  mmol/L in  $\geq 36\%$  of patients, with 42.3% ( $n=33$ ) fulfilling the criterion in the group diagnosed with DM2  $\leq 5$  years ago and 64.1% ( $n=164$ ) fulfilling the criterion in the group diagnosed with DM2  $>5$  years ago ( $P$ -difference=0.0006). No statistically significant differences in the LDL-cholesterol targets were observed in participants diagnosed with DM1  $\leq 5$  years or  $>5$  years ago.

The complete set of results stratified by diabetes type and time since diabetes diagnosis are available in online supplementary tables 2-3.

## CONCLUSIONS

Here we analyzed baseline data of 604 SwissDiab participants with DM1 and DM2 with respect to compliance with a subset of SSED national guidelines for good disease management in diabetes focused mainly on clinical and biochemical targets.<sup>13</sup> The results show that the majority of the criteria under study were achieved in a tertiary care setting. Exceptions were annual nutrition counseling in  $\geq 80\%$  of patients with a BMI  $\geq 25$  kg/m<sup>2</sup> which was not achieved in either the DM1 or DM2 group, and an HbA1c  $<7\%$  in  $\geq 40\%$  of patients which was not reached among participants with DM1. However, taking into consideration duration of diabetes, the SSED target of an HbA1c  $<7\%$  in  $\geq 40\%$  of patients was achieved among participants diagnosed  $\leq 5$  years ago, regardless of diabetes type. Considering participants diagnosed with DM2  $>5$  years ago, the SSED target was no longer met, illustrating that compliance with treatment targets is partly dependent on the composition of the patient group. Overall, the results reflect a comparably high standard of diabetes care among SwissDiab participants at the two tertiary care centers in the German-speaking part of Switzerland.

The sex distribution in SwissDiab was similar to that observed among the 392 participants (68% men and 32% women) with DM2 in the CoLaus study, a population-based cross-sectional study of  $>6000$  adults living in Lausanne, in the French-speaking part of Switzerland.<sup>16</sup> Both results are in line with national data on the prevalence of diabetes based on the 2012 Swiss Health Survey (6% among men and 4% among women) and earlier studies.<sup>17 18</sup> A relatively high proportion of DM1 compared with DM2 in SwissDiab is expected. Given the complexity of maintaining glycemic control in DM1, these patients are often referred to tertiary care which has more experience and expertise in treatment options (eg, implementation of new technologies, flexible insulin therapy, and diabetes education).

Epidemiological data regarding clinical characteristics as well as quality of care of patients with diabetes in Switzerland are scarce. In the 1970s, the WHO Multinational Study of Vascular Disease in Diabetes was established with the aim to compare prevalence of vascular disease in diabetes.<sup>19 20</sup> In 2009, Allemann *et al* conducted a 30-year follow-up in the 533 Swiss participants recruited by local

practitioners.<sup>5</sup> All-cause and cardiovascular mortality was higher in participants with DM1 and DM2 compared with the general population, but decreased during the last two decades, indicating improved treatment strategies.

In 2011, Gerber *et al* published data on 1121 patients with DM2 treated by general practitioners in the four linguistic regions (German, French, Italian, and Romansh) of Switzerland.<sup>21</sup> The mean HbA1c level was  $6.9\% \pm 1.0\%$  in the German-speaking region compared with  $7.3\% \pm 1.1\%$  (median 7.1% (6.6–7.9)) in SwissDiab. Furthermore, mean BMI ( $29.5 \pm 5.4$  kg/m<sup>2</sup>) as well as BP (SBP,  $138.2 \pm 16.4$  mm Hg; DBP,  $81.1 \pm 10.4$  mm Hg) tended to be lower in the study by Gerber *et al* compared with the SwissDiab study (BMI, mean= $32.8 \pm 6.2$  kg/m<sup>2</sup>, median= $32.1$  kg/m<sup>2</sup> (28.4–36.5); SBP, mean= $138.7 \pm 16.6$  mm Hg, median= $138.0$  mm Hg (127.0–149.5); DBP, mean= $77.4 \pm 10.0$  mm Hg, median= $77.5$  mm Hg (72.0–83.5)), suggesting that the metabolic profile of participants in the former study was better, which is not surprising given the different clinical settings in which the participants of the two studies were recruited. Mean age at diagnosis of DM2 in SwissDiab was  $48.3 \pm 10.4$  years (median 48.0 years (42.0–56.0)), and the mean age at start of therapy in the study by Gerber *et al* was  $60.9 \pm 11.2$  years. Given that antidiabetic treatment is generally initiated within 1 year of diagnosis,<sup>14</sup> this might indicate an earlier onset and a more advanced and progressive course of disease in the SwissDiab participants, which would be in line with the tertiary care setting in which participants were recruited. It is also possible that variations in diabetes therapy contribute to the differences; however, data on medication are not yet available in SwissDiab.

In 2013, Burgmann *et al* published a retrospective study comparing data of all patients with DM2 admitted to the general clinic of medicine at the Hospital Centre Biel in 2009 to the treatment recommendations published by the SSED the same year.<sup>12 22</sup> Mean age was higher compared with the SwissDiab participants ( $74.2 \pm 10.8$  years vs  $61.3 \pm 10.4$  years, median= $62.1$  years (54.7–68.8)) as was the mean HbA1c ( $7.7\% \pm 1.7\%$  vs  $7.3 \pm 1.1\%$ ; median= $7.1\%$  (6.6–7.9)).<sup>22</sup> The authors concluded that metabolic control was suboptimal in the majority of patients with DM2 and implementations of treatment guidelines by general practitioners as well as hospitals need to be improved. However, the results may rather reflect a greater disease burden of hospitalized patients with DM2, and as such, may not reflect a general failure to adhere to treatment guidelines. Burgmann *et al* do not provide detailed information on disease burden or the reason behind hospitalization but 44% of patients with DM2 presented with an HbA1c level  $\leq 7\%$ , which is similar to the proportion seen in the tertiary setting of SwissDiab. Furthermore, 20% had an HbA1c  $>8.5\%$  (11% in SwissDiab), supporting the assumption that glycemic control in individuals with DM2 and need of hospitalization tends to be worse compared with patients in outpatient clinics.

In 2014, Zuercher *et al* published baseline data from the CoDiab-VD Study, a population-based cohort of participants with diabetes recruited in the French speaking canton of Vaud.<sup>23</sup> Of the 519 participants, 67% were diagnosed with DM2. Mean age and diabetes duration were similar to that observed in SwissDiab. Self-reported HbA1c was available in 177 participants (34%) with unspecified diabetes type and was similar to baseline HbA1c in the SwissDiab DM1 and DM2 groups (7.3% (95% CI 7.1 to 7.5) vs 7.5% (95% CI 7.3 to 7.6) and 7.3% (95% CI 7.2 to 7.4), respectively).<sup>23</sup> The recruitment strategy via community pharmacies (participation rate <50%) has the potential to capture a more health-conscious fraction of the target population. Further assuming that HbA1c-aware participants are more health-conscious and therefore better controlled, the HbA1c level is likely to be an underestimation of the population average. General practitioners might measure HbA1c less frequently in patients with milder forms of diabetes, for example, those treated only with oral antidiabetic medication (51% in CoDiab-VD), or might communicate good HbA1c levels less actively as they may not have an immediate therapeutic consequence. With the limited information provided, it is difficult to draw any conclusions regarding differences in disease severity between the two studies.

The SSED targets for LDL-cholesterol were met in both SwissDiab and the inpatients with DM2 in Burgmann *et al*.<sup>22</sup> Lack of information in the study by Gerber *et al* and in CoDiab-VD precludes comparisons with these study populations.<sup>21 23</sup> That LDL-cholesterol was better controlled in the DM2 compared with the DM1 group is to be expected as cardiovascular risk is higher in DM2 compared with DM1 in the absence of secondary complications. Therefore, one can assume that the proportion of participants on statins was higher in the DM2 group. Higher mean total and LDL-cholesterol levels in participants diagnosed with DM2  $\leq 5$  years ago were unexpected. Given the better glycemic control in this group, one possible explanation is that healthcare professionals in charge are less stringently targeting lipids. Suboptimal adherence to prescribed lipid-lowering medications might also be an explanation. However, information on medication is not yet available for analysis in SwissDiab.

Out of 511 participants in CoDiab-VD, 58% attended an ophthalmic examination during the previous year,<sup>23</sup> whereas the SSED target of  $\geq 80\%$  was achieved in SwissDiab. How representative these results are to the primary care setting is unclear. It is possible that patients with more severe diabetes, as often is the case in tertiary settings, are more carefully screened.

The SSED criterion regarding weight maintenance addresses the importance of raising patient awareness of the central role of weight and diet for good diabetes management through annual discussions with the healthcare provider. In CoDiab-VD, written or verbal diet recommendations were received by 49% of the participants.<sup>23</sup> Distinction between DM1 and DM2, or based on BMI category was not provided, preventing

direct comparisons with SwissDiab, where 47% and 56% of overweight/obese participants with DM1 and DM2, respectively, received nutrition counseling. Irrespectively, this area of diabetes care and management can clearly be improved. The primary focus of the SSED criteria is the primary care setting, where fostering of healthy lifestyle choices likely has the potential to substantially reduce the risk of future need of tertiary care, improve quality of life and reduce the burden on healthcare systems. Future studies assessing compliance in the primary care setting are therefore warranted.

Applying diabetes care targets primarily aimed at the primary care setting to tertiary care could be considered too stringent as the patient group of the latter likely includes patients with a more advanced and progressive course of disease where, for example, glycemic control is likely harder to achieve. On the other hand, benefits of intensive multifactorial therapy in reducing microvascular and/or macrovascular complications have been shown,<sup>2 24-26</sup> and might thus be beneficial to the high-risk patient group with diabetes treated in tertiary care. As this study illustrates, it is possible to adhere to the majority of the SSED targets in this high-risk patient group. However, although shown to be beneficial, intensive therapy including tight glycemic control has also been associated with increased mortality in high-risk individuals with DM2,<sup>27</sup> emphasizing that on the individual level, treatment goals should always be based on patient-specific characteristics, including risk of hypoglycemia, diabetes duration, life expectancy, comorbidities, and other relevant factors.<sup>12</sup> Longitudinal studies of the SwissDiab participants will be able to assess whether adherence to the SSED targets influences incidence of diabetes-related complications and comorbidities in this patient group.

The main limitation is that the study is based on two out of the six largest tertiary diabetes care centers in the German-speaking part of Switzerland. Although similar hospital standards and access to care are expected, the generalizability of the results to tertiary care in the German-speaking part and Switzerland as a whole is unclear. To what extent the enrolled patients are representative of the patient group at large at the two centers is also not known, but currently under investigation. A further limitation is that not all of the SSED criteria could be assessed due to lack of information on physical activity and smoking cessation counseling, and the inability to provide meaningful data on the performance of nephropathy screenings and foot exams that would be representative of the general clinical practice at the tertiary care centers involved, as these two exams are an integral parts of the annual SwissDiab examination.

As patients treated at tertiary care centers are more likely to present with advanced disease stages and diabetes-related complications, the study population represents a patient group that generally requires a large proportion of healthcare resources. It is thus important to obtain information on the status of quality of care



and treatment in this patient group. Next to CoDiab-VD, SwissDiab is the largest observational study in Switzerland including patients with DM1 and DM2. The longitudinal setting and standardized annual examinations gain advantage over the CoDiab-VD Study, which is based largely on self-report. SwissDiab is thus a resource that has the potential to provide comprehensive and significant information on diabetes care in Switzerland. This will be of vital importance for decision makers in politics and the health sector in view of rising patient numbers and limited financial resources. As additional study centers are recruited, including the other language regions, SwissDiab will continue to give an even more complete picture on the quality of diabetes care and patient outcomes in Switzerland in the future.

**Acknowledgements** The authors thank the participants, health professionals, and data managers involved in the SwissDiab Registry.

**Collaborators** Peter Diem, Markus Laimer, Andreas Melmer; Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, University Hospital Bern; Switzerland. Roger Lehmann, Philipp Gerber, Jan Krützfeldt; Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Switzerland

**Contributors** MB conceptualized the research question, KES and MB led the study design, CS and MB provided data, FR and SM performed the statistical analysis, FR and KES interpreted the results and drafted the manuscript. All authors made critical revision of the article for key intellectual content and approved the final version of the manuscript.

**Funding** Funding for SwissDiab was received from the Swiss Diabetes Foundation, CTU Cantonal Hospital St.Gallen, unrestricted grants from pharmaceutical companies (alphabetical order): Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Novo Nordisk, Roche, Sanofi.

**Disclaimer** None of the funders had any active role in the design of the study, collection, analysis or interpretation of the data, or in the writing of the paper.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** The study protocol was approved by the cantonal ethics committees of St. Gallen and Bern (EKSG09/114/L) and conducted in accordance with the Declaration of Helsinki.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Data not publicly available

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

- Nathan DM, Genuth S, Lachin J, *et al.* The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–86.
- UK Prospective Diabetes Study (UKPS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–53.
- Holman RR, Paul SK, Bethel MA, *et al.* 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- Nathan DM, Cleary PA, Backlund JY, *et al.* Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:2643–53.
- Allemann S, Saner C, Zwahlen M, *et al.* Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. *Swiss Med Wkly* 2009;139(39-40):576–83.
- Chen Y, Sloan FA, Yashkin AP. Adherence to diabetes guidelines for screening, physical activity and medication and onset of complications and death. *J Diabetes Complications* 2015;29:1228–33.
- Saleh F, Mumu SJ, Ara F, *et al.* Non-adherence to self-care practices & medication and health related quality of life among patients with type 2 diabetes: a cross-sectional study. *BMC Public Health* 2014;14:431.
- Wong ES, Bryson CL, Hebert PL, *et al.* Estimating the Impact of Oral Diabetes Medication Adherence on Medical Costs in VA. *Ann Pharmacother* 2014;48:978–85.
- Guess ND, Caengprasath N, Dornhorst A, *et al.* Adherence to NICE guidelines on diabetes prevention in the UK: Effect on patient knowledge and perceived risk. *Prim Care Diabetes* 2015;9:407–11.
- Rao DT, Sunio LK, Lo YJ, *et al.* Comparison of the adherence to the american diabetes association guidelines of diabetes care in primary care and subspecialty clinics. *J Diabetes Metab Disord* 2015;14:35.
- NCQA. Diabetes Recognition Program (DRP). <http://www.ncqa.org/Programs/Recognition/DiabetesRecognitionProgramDRP.aspx> (accessed June 2017).
- Philippe J, Brändle M, Carrel J, *et al.* Massnahmen zur Blutzuckerkontrolle bei Patienten mit Typ-2-Diabetes-Mellitus. Consensus Statement der Schweizerischen Gesellschaft für Endokrinologie und Diabetes (SGED). *Schweiz Medical Forum* 2009;9:50–5.
- Swiss Society of Endocrinology and Diabetology (SSED). Kriterien für ein 'gutes' Disease Management Diabetes in der Grundversorgung. 2014. [http://sgedssed.ch/fileadmin/files/6\\_empfehlungen\\_fachpersonen/63\\_praxis-empfehlungen/Kriterien-DMD\\_v2014\\_14-08-19.pdf](http://sgedssed.ch/fileadmin/files/6_empfehlungen_fachpersonen/63_praxis-empfehlungen/Kriterien-DMD_v2014_14-08-19.pdf) (accessed June 2017).
- American Diabetes Association. Standards of Medical Care in Diabetes-2017. *Diabetes care* 2017;40(Suppl 1):S1–S135.
- Davis TM, Zimmet P, Davis WA, *et al.* Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. *Diabet Med* 2000;17:667–74.
- Kaiser A, Vollenweider P, Waeber G, *et al.* Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. *Diabet Med* 2012;29:190–7.
- Federal Statistical Office. Swiss Health Survey 2012: overview. [www.bfs.admin.ch/bfs/en/home/statistics/catalogues-databases/publications.assetdetail.349060.html](http://www.bfs.admin.ch/bfs/en/home/statistics/catalogues-databases/publications.assetdetail.349060.html) (accessed June 2017).
- Bopp M, Zellweger U, Faeh D. Routine data sources challenge international diabetes Federation extrapolations of national diabetes prevalence in Switzerland. *Diabetes Care* 2011;34:2387–9.
- Jarrett RJ, Keen H, Grabauskas V. The WHO multinational study of vascular disease in diabetes: 1. General description. *Diabetes Care* 1979;2:175–86.
- Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. *Diabetologia* 1985;28 Suppl:615–40.
- Gerber PA, Spirk D, Brändle M, *et al.* Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. *Swiss Med Wkly* 2011;141:w13218.
- Burgmann K, Fatio S, Jordi B, *et al.* Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis. *Swiss Med Wkly* 2013;143:w13871.
- Zuercher E, Casillas A, Hagon-Traub I, *et al.* Baseline data of a population-based cohort of patients with diabetes in Switzerland (CoDiab-VD). *Swiss Med Wkly* 2014;144:w13951.
- Patel A, MacMahon S, Chalmers J, *et al.* Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–72.
- Gaede P, Lund-Andersen H, Parving HH, *et al.* Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358:580–91.
- Gaede P, Vedel P, Larsen N, *et al.* Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383–93.
- Gerstein HC, Miller ME, Byington RP, *et al.* Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–59.